Search Results
Sep 08, 2026, 06:19 ET Extraordinary in Hand, Effortless in Control HUAWEI Mate XT 2 | ULTIMATE DESIGN Debuts as the First Smartphone to Feature LogicFolding Tau (τ) Chip and Reach Mass Commercialization
computing capability, supporting multi-sized large models. For the first time in the industry, it natively supports the on-device Pangu Large Model (30B-A2B), enabling smart experiences such as on-device AI album management with Celia.The innovative heat dissipation architecture distributes heat
More news about: Huawei
Sep 08, 2026, 06:11 ET AVEX INVESTOR DEADLINE: AEVEX Corp. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - October 20, 2026 Deadline
a 180-day "lock-up" and therefore prevent Madison Dearborn Partners, LLC from selling its Class A common stock or converting or exchanging its Class B or LLC Units into Class A common stock for public sale until at least October 13, 2026, defendants concealed a pre-arranged plan between Madison Dearborn
More news about: Robbins Geller Rudman & Dowd LLP
Sep 08, 2026, 06:11 ET Modern Micro Endodontics Opens Ninth New Jersey Location in Englewood Cliffs
Hoboken, NJ 07030, 201-386-9080Millburn: 187 Millburn Ave, Suite 7, Millburn, NJ 07041, 973-258-9535Cedar Grove: 900 Pompton Ave, Ste B1, Cedar Grove, NJ 07009, 973-655-9080North Plainfield: 339 Somerset St, North Plainfield, NJ 07060, 908-650-7200Parsippany: 245 Baldwin
More news about: Modern Micro Endodontics
Sep 08, 2026, 06:07 ET YSS Lawsuit Alert: York Space Systems Investors Face October 30 Deadline After 10% Stock Drop Tied to Satellite Software Issues
to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased or otherwise acquired York Space Systems common stock pursuant
More news about: Bleichmar Fonti & Auld LLP
Sep 08, 2026, 06:07 ET UWMC Lawsuit Alert: UWM Holdings Investors Face October 13 Deadline After 34% Stock Drop Tied to Hedging Strategy Issues
until October 13, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in UWM securities. The class action is pending in the U.S. District Court for
More news about: Bleichmar Fonti & Auld LLP
Sep 08, 2026, 06:07 ET INV Lawsuit Alert: Innventure Investors Face October 27 Deadline After 55% Stock Drop Tied to Data Center Deal Cancellation
until October 27, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Innventure securities. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Sep 08, 2026, 06:06 ET RXT Lawsuit Alert: Rackspace Technology Investors Face September 28 Deadline After 33% Stock Drop Tied to AI Effort Issues
until September 28, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Rackspace securities. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Sep 08, 2026, 06:06 ET GDDY Lawsuit Alert: GoDaddy Investors Face October 26 Deadline After 14% Stock Drop Tied to Customer Acquisition Issue
until October 26, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in GoDaddy common stock. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Sep 08, 2026, 06:06 ET CAPR Lawsuit Alert: Capricor Therapeutics Investors Face September 28 Deadline After 64% Stock Drop Tied to Clinical Data Disclosure
until September 28, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Capricor securities. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Sep 08, 2026, 06:01 ET PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
PMB-CT01PMB-CT01 is a first-in-class B-cell activating factor receptor (BAFF-R)-targeted autologous CAR T-cell therapy being evaluated in ongoing Phase 1 trials for relapsed/refractory B-NHL and relapsed/refractory B-ALL. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio gibt die Veröffentlichung bahnbrechender Ergebnisse einer klinischen Phase-1-Studie in The Lancet bekannt, die tiefe und anhaltende vollständige Remissionen bei rezidivierten/refraktären B-Zell-Lymphomen belegen, auch nach vorherigem Versagen einer CD19-CAR-T-Zell-Therapie
den Rezeptor für den B-Zell-aktivierenden Faktor (BAFF-R) abzielt und derzeit in laufenden Phase-1-Studien bei rezidiviertem/refraktärem B-NHL sowie rezidivierter/refraktärer B-ALL untersucht wird. BAFF-R wird fast ausschließlich auf B-Zellen exprimiert und ist für das Überleben der B-Zellen unerlässlich,
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
PMB-CT01PMB-CT01 is a first-in-class B-cell activating factor receptor (BAFF-R)-targeted autologous CAR T-cell therapy being evaluated in ongoing Phase 1 trials for relapsed/refractory B-NHL and relapsed/refractory B-ALL. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio annonce la publication dans The Lancet des résultats d'un essai clinique de phase 1 démontrant des réponses complètes profondes et durables dans les lymphomes à cellules B récidivants ou réfractaires, y compris après l'échec d'un traitement par cellules CAR-T ciblant le CD19
d'activation des lymphocytes B (BAFF-R), actuellement évaluée dans le cadre d'essais cliniques de phase I en cours pour le traitement des LNH de type B récidivants/réfractaires et des LAL de type B récidivantes/réfractaires. Le BAFF-R est exprimé presque exclusivement sur les cellules B et est essentiel pour
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio anuncia la publicación en The Lancet de los resultados de su ensayo clínico de fase 1
activador de células B (BAFF-R), la primera de su clase, que se está evaluando en ensayos de fase 1 en curso para linfoma no Hodgkin de células B de recaída/refractario y leucemia linfoblástica aguda de células B de recaída/refractaria. BAFF-R se expresa casi exclusivamente en las células B y es esencial para
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET 페프로민 바이오, 기존 CD19 CAR T세포 치료 실패 포함 재발성/불응성 B세포 림프종에서 깊고 지속적인 완전관해 입증한 제1상 임상시험 결과 랜싯에 게재 발표
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01329-2/fulltextPMB-CT01 소개PMB-CT01은 재발성/불응성 B-NHL 및 재발성/불응성 B-ALL을 대상으로 현재 진행 중인 제1상 임상시험에서 평가되고 있는 혁신신약 BAFF-R 표적 자가 CAR T세포 치료제다. BAFF-R은 거의 독점적으로 B세포에서 발현되며 B세포 생존에 필수적이어서 항원 소실에 의한 면역 회피 가능성을 낮춘다. 페프로민
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:00 ET 스파이록스, 유리 기판 양산 검사를 지원하는 고속 TGV 크랙 검사 시스템 출시
multimedia:https://www.prnewswire.com/kr/news-releases/uC2A4uD30CuC774uB85DuC2A4u002Cu002DuC720uB9ACu002DuAE30uD310u002DuC591uC0B0u002DuAC80uC0ACuB97Cu002DuC9C0uC6D0uD558uB294u002DuACE0uC18Du002D-302872141.htmlSOURCE
More news about: Spirox Corporation
Sep 08, 2026, 06:00 ET Brig Gen (Ret.) Jason Hawk Joins CoAspire as an Executive Vice President
capability development and modernization efforts supporting programs including Next Generation Air Dominance, Collaborative Combat Aircraft, C3BM, and B-21."Jason's experience sits directly at the intersection of where CoAspire is today and where we are going," said Doug Denneny, Founder and CEO of
More news about: CoAspire
Sep 08, 2026, 06:00 ET Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend
The timing and dollar amount of repurchase transactions will be subject to the requirements of the Securities and Exchange Commission Rule 10b-18 and/or Rule 10b5-1. The Board will review the share repurchase program periodically, and may authorize adjustment to its terms and size or suspend or discontinue
More news about: Waterdrop Inc.
Sep 08, 2026, 06:00 ET Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Fourth Quarter and Fiscal Year Ended June 30, 2026
transactions, in block trades, and/or through other legally permissible means, including through the use of trading plans, intended to qualify under Rule 10b-18 under the Securities Exchange Act of 1934, as amended, in accordance with applicable securities laws and other restrictions and subject to market conditions
More news about: Gamehaus Holdings Inc.
Sep 08, 2026, 04:30 ET Hang Feng Technology Innovation Co., Ltd. Announces First Half 2026 Financial Results
statutory capital structure was reorganized into 9,000,000,000 Class A Ordinary Shares and 1,000,000,000 Class B Ordinary Shares. As of June 30, 2026, 3,871,000 Class A Ordinary Shares and 4,000,000 Class B Ordinary Shares were issued and outstanding.Regulatory Licenses: Through its Hong Kong
More news about: Hang Feng Technology Innovation Co., Ltd.
Sep 08, 2026, 04:17 ET Epicyt Pharma reports positive results in first-in-human study of BAFA in patients following gastric bypass surgery
together with improvements in key biomarkers of calcium homeostasis. Based on these encouraging findings, Epicyt is preparing to advance BAFA into Phase 2b development. "In our short proof-of-concept study aimed at showing an immediate calcium balance-effect of our drug candidate, BAFA produced
More news about: Epicyt Pharma AB
Sep 08, 2026, 04:00 ET IsoEnergy Completes Summer Drilling at Larocque East, Intersecting Widespread and Strongest Radioactivity to Date Along the Hurricane South Trend
with a peak reading of 1,190 cps over a 0.5 m interval.J and K Fault TargetsDrillholes LE26-251, LE26-258, LE26-259, LE26-260, LE26-265B, and LE26-267 targeted interpreted J fault at the unconformity.LE26-251 was drilled to test the J fault at the unconformity (see news
More news about: IsoEnergy Ltd.
Sep 08, 2026, 03:40 ET 화웨이와 파트너사, 아시아•태평양 지역에서 4대 AI+ 헬스케어 시나리오 솔루션 공동 출시
multimedia:https://www.prnewswire.com/kr/news-releases/uD654uC6E8uC774uC640u002DuD30CuD2B8uB108uC0ACu002Cu002DuC544uC2DCuC544u2022uD0DCuD3C9uC591u002DuC9C0uC5EDuC5D0uC11Cu002Du0034uB300u002Du0061-302872018.htmlSOURCE
More news about: Huawei
Sep 08, 2026, 03:38 ET EQPT Investors Have Opportunity to Lead EquipmentShare.com Inc. Securities Fraud Lawsuit with SBS Law
EQPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of
More news about: Schall, Brown & Schwartz LLP
Sep 08, 2026, 03:37 ET CCOI Investors Have Opportunity to Lead Cogent Communications Holdings, Inc. Securities Fraud Lawsuit with SBS Law
CCOI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of
More news about: Schall, Brown & Schwartz LLP